Drug development challenges in nontuberculous mycobacterial lung disease: TB to the rescue.

The Journal of experimental medicine, Volume: 219, Issue: 6
June 6, 2022
VĂ©ronique Dartois V, Thomas Dick T

Nontuberculous mycobacterial pulmonary disease (NTM-PD) is treated with multiple repurposed drugs. Chemotherapy is long and often toxic, includes parenteral drugs, and suffers from poor cure rates. There is an urgent need for more efficacious, tolerated, and oral antibiotics optimized towards the treatment of NTM-PD, adapted to the spectrum of disease. In contrast to the empty NTM pipeline, drug development for the related tuberculosis lung disease has experienced a renaissance. Here, we argue that applying lessons learned from tuberculosis will facilitate the discovery of curative oral regimens for NTM-PD.

Courtesy of the U.S. National Library of Medicine